A Phase 3 interventional study of Evolocumab in Dyslipidemia, sponsored by Amgen. Terminated at 85 sites in 7 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing evolocumab in Dyslipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Dyslipidemias.
Among the 10 studies testing evolocumab in Dyslipidemias, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 7th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 10 studies testing evolocumab in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,600 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 409 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 9 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing evolocumab in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label extension (OLE) study designed to assess the extended long-term safety of evolocumab in subjects who have completed the FOURIER trial (Study 20110118). Approximately 1600 subjects will be enrolled in this study. This study will continue for 260 weeks (approximately 5 years).
This is a multicenter, open-label extension (OLE) study designed to assess the extended long-term safety of evolocumab in subjects who have completed the FOURIER trial (Study 20110118). FOURIER is a randomized placebo-controlled study of evolocumab, in patients with clinically evident atherosclerotic CVD on stable effective statin therapy. Subjects at sites participating in FOURIER OLE (Study 20160250) who are eligible and have signed the FOURIER OLE informed consent will be enrolled after completion of FOURIER.
The FOURIER OLE study requires laboratory assessments at day 1, week 12, and thereafter approximately every 6 months from day 1; the corresponding blood samples will be processed using a central laboratory.
Upon enrollment in FOURIER OLE study, subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM) according to their preference. Frequency and corresponding dose of administration can be changed at any scheduled time point where evolocumab is supplied to the subject, provided the appropriate supply is available. It is recommended that subjects continue the same background lipid-lowering therapy (LLT), including statin, as taken during FOURIER.
This study will continue for 260 weeks (approximately 5 years). Subjects ending administration of evolocumab should continue study assessments until the end of study. All subjects will be followed and complete procedures/assessments from enrollment through the date of study termination unless the subject has withdrawn consent, irrespective of whether the subject is continuing to receive treatment.
All deaths and cardiovascular events of interest will be reviewed by an independent external Clinical Events Committee (CEC), using standardized definitions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm study administering Evolocumab.
Drug: Evolocumab
Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
Also known as: AMG 145
Number of Participants Who Experienced an Adverse Event
All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.
Time frame: Up to 5 years
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit
Time frame: Baseline, Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL
Time frame: Baseline, Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
This was an open-label extension of study 20110118 (NCT01764633). Eligible participants were enrolled after the completion of the 20110118 study. 1600 participants were enrolled at 86 centers in Belgium, Germany, Denmark, France, Italy, Portugal, and Sweden from 13 March 2017 to 04 March 2022.
| Milestone | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study |
|---|---|---|
| Started | 745 | 855 |
| Completed | 695 | 786 |
| Not completed | 50 | 69 |
| Withdrew: Death | 34 | 50 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Withdrawal by subject | 11 | 15 |
All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.
| Participants | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event | 686 | 810 |
| Percent Change | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study |
|---|---|---|
| Week 12 | -66.32 ± 26.88 | -67.24 ± 25.23 |
| Week 24 | -66.48 ± 27.52 | -66.47 ± 28.11 |
| Week 48 | -62.61 ± 26.60 | -63.45 ± 26.03 |
| Week 72 | -65.58 ± 28.13 | -65.33 ± 28.42 |
| Week 96 | -64.58 ± 27.01 | -63.43 ± 28.80 |
| Week 120 | -64.26 ± 28.31 | -63.10 ± 29.56 |
| Week 144 | -66.79 ± 29.22 | -65.13 ± 31.96 |
| Week 168 | -65.28 ± 27.55 | -63.55 ± 29.60 |
| Week 192 | -65.02 ± 27.93 | -62.46 ± 26.39 |
| Week 216 | -64.92 ± 27.93 | -62.46 ± 28.32 |
| Week 260 | -66.45 ± 29.84 | -64.72 ± 29.50 |
| Percentage of Participants | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study |
|---|---|---|
| Baseline in parent study | 0 (0.0 to 0.5) | 0 (0.0 to 0.4) |
| Week 12 | 72.8 (69.4 to 75.9) | 72.5 (69.4 to 75.4) |
| Week 24 | 72.9 (69.5 to 76.0) | 73.4 (70.3 to 76.2) |
| Week 48 | 66.5 (63.0 to 69.9) | 68.0 (64.8 to 71.1) |
| Week 72 | 73.2 (69.8 to 76.3) | 72.3 (69.1 to 75.2) |
| Week 96 | 71.1 (67.6 to 74.3) | 69.2 (65.9 to 72.3) |
| Week 120 | 70.9 (67.5 to 74.2) | 68.6 (65.3 to 71.8) |
| Week 144 | 75.3 (71.2 to 78.9) | 72.2 (68.5 to 75.7) |
| Week 168 | 72.3 (68.8 to 75.6) | 69.3 (65.9 to 72.5) |
| Week 192 | 71.6 (67.9 to 74.9) | 66.3 (62.8 to 69.7) |
| Week 216 | 72.1 (68.6 to 75.4) | 67.3 (63.9 to 70.6) |
| Week 260 | 76.1 (71.6 to 80.2) | 68.8 (64.2 to 73.0) |
Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo in Parent Study | 35/745 (4.7%) | 323/745 (43.4%) | 451/745 (60.5%) |
| Evolocumab in Parent Study | 51/855 (6%) | 410/854 (48%) | 528/854 (61.8%) |
| Event | Placebo in Parent Study | Evolocumab in Parent Study |
|---|---|---|
| Angina pectorisCardiac disorders | 26/745 | 24/854 |
| Cardiac failureCardiac disorders | 17/745 | 27/854 |
| Atrial fibrillationCardiac disorders | 15/745 | 22/854 |
| Acute myocardial infarctionCardiac disorders | 18/745 | 15/854 |
| PneumoniaInfections and infestations | 15/745 | 19/854 |
| Angina unstableCardiac disorders | 15/745 | 13/854 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 8/745 | 15/854 |
| Ischaemic strokeNervous system disorders | 8/745 | 14/854 |
| Peripheral arterial occlusive diseaseVascular disorders | 12/745 | 12/854 |
| SyncopeNervous system disorders | 10/745 | 10/854 |
| Event | Placebo in Parent Study | Evolocumab in Parent Study |
|---|---|---|
| HypertensionVascular disorders | 132/745 | 150/854 |
| NasopharyngitisInfections and infestations | 75/745 | 111/854 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 61/745 | 75/854 |
| Back painMusculoskeletal and connective tissue disorders | 50/745 | 70/854 |
| Diabetes mellitusMetabolism and nutrition disorders | 60/745 | 57/854 |
| MyalgiaMusculoskeletal and connective tissue disorders | 55/745 | 47/854 |
| InfluenzaInfections and infestations | 37/745 | 53/854 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 24/745 | 50/854 |
| Atrial fibrillationCardiac disorders | 37/745 | 49/854 |
| CataractEye disorders | 42/745 | 32/854 |
The Overall Number of Baseline Participants is made up of all of the participants that received study drug.
| Age, Continuous(Years) | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Total |
|---|---|---|---|
| Mean | 62.7 ± 9.1 | 62.6 ± 8.9 | 62.6 ± 9.0 |
| Sex: Female, Male(Participants) | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Total |
|---|---|---|---|
| Female | 138 | 151 | 289 |
| Male | 607 | 703 | 1310 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 24 | 41 |
| Not Hispanic or Latino | 728 | 830 | 1558 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Black or African American | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| White | 706 | 797 | 1503 |
| Multiple | 0 | 0 | 0 |
| Other | 38 | 53 | 91 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2017 to primary completion in Mar 2022, 59 months.
Results were first posted in Jan 2023, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab